Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Sera Prognostics Inc.

Sera Prognostics ( ($SERA) ) just unveiled an update. On June 4, 2026, Sera Prognostics, Inc. held its 2026 Annual Meeting of Stockholders via live...

Sera Prognostics Holds 2026 Annual Stockholders Meeting

The latest update is out from Sera Prognostics ( ($SERA) ). On May 26, 2026, Sera Prognostics director Jeffrey T. Elliott notified the company he w...

Current Quarter	$-0.14	Next Quarter	$-0.14
Current Year	$-0.58	Next Year	$-0.51
QoQ Growth	+0.0%	YoY Growth	+12.1%
3Y EPS CAGR	+22.3%	Target Price	$5.50
Consensus	Buy	Upside	+214.3%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SERA	$1.75	-7.41%	87.46K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SERA	$1.75	-7.4%	87.46K
3
4
5
6

SERA

SERA

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Sera Prognostics Inc. Data in Excel

Get Sera Prognostics Inc. Data in Excel